Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| SUPERNUS PHARMACEUTICALS, INC.SUPN · Entity 4333 | Director | June 13, 2017 | June 15, 2017 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
SUPERNUS PHARMACEUTICALS, INC.
Report date June 13, 2017 · Filed June 15, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Director Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $38.60 · Expires 2027-06-13 | Direct | 6,036 |
Reported balance
After 2017-06-13 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2017-06-13 · Grant · Acquired 6,036 · Balance 6,036 |
| Common StockSEC Table I · non-derivative | Direct | 23,750 |
Reported balance
Holding disclosure · report date 2017-06-13 · row 1
Holding and transaction disclosures are not merged.
1 source rowRow 1 · Balance 23,750 |
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 13, 2017 Filed Jun 15, 2017 20:42 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 6,036 | $0.00 Strike: $38.60 | $0.00 |
DisclosureSEC source: 0001104659-17-039593 · a4.xml · derivative · entry 2 Nuerge William A. · CIK 0001540039 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,036 Underlying: Common Stock · 6,036 shares Expires 2027-06-13 Read SEC document |
| February 24, 2017 Filed Feb 28, 2017 02:55 UTC | SUPERNUS PHARMACEUTICALS, INC. SUPN · Entity 4333 | GrantDirector Stock Option (Right to Buy) · Derivative | 7,905 | $0.00 Strike: $25.30 | $0.00 |
DisclosureSEC source: 0001104659-17-012169 · a4.xml · derivative · entry 2 Nuerge William A. · CIK 0001540039 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,905 Underlying: Common Stock · 7,905 shares Expires 2027-02-24 Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.